Bracco

To see an up-to date selection of historical analyses and insights on Bracco, visit our new, dynamically updated Company Summary report pages for Bracco.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Bracco are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Bracco, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers
  Annual Sales WW - Sales Growth per Year (%)
  Rank Product Generic Name Pharmacological Class 2006 2007 2007
Bracco 1 Isovue iopamidol X Ray contrast media 674 805   19%  
 
  Note: Shaded Cells  

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
Bracco
  2005 2006
 Valuation Measures
  Based on Latest Share Prices
     Valuing the Equity
 
     Valuing the Enterprise
 
 Forecast Financials
  Income Statement
     Total Revenues 0 0
     Other Income/ Expense - Net 0 0
     Tax 0 0
     Net Income - Reported 0 0
     Net Income - Normalised 0 0
 
  Per Share Data
     DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)
Therapeutic focus – diagnostic agents gaining clarity   (Molecular Insight Pharmaceuticals)   08-Dec-2008
Non-Ionic Contrast Agents, Iomeron® 350 and Iomeron® 350 Syringe, Receive Approval for Use in Dynamic CT Liver Imaging   (Eisai)   22-May-2008

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
 
  Product Generic Name
Bracco CardioGen-82 rubidium Rb-82 chloride
  Cardiotec technetium Tc-99m teboroxime
  Cebion ascorbic acid
  Choletec technetium Tc-99m mebrofenin
  Cholografin iodipamide meglumine
  Chromitope sodium chromate Cr-51
  Cystografin diatrizoate meglumine
  Digibar barium sulfate
  Esopho-CAT barium sulfate
  E-Z-CAT Dry barium sulfate
  Ferriseltz ferric ammonium citrate
  Gastrografin diatrizoate meglumine & diatrizoate sodium
  Gastromiro iopamidol
  Iodotope sodium iodide I-131
  Iomeron iomeprol
  Isovue iopamidol
  Kinevac sincalide
  LoSo Prep bisacodyl, magnesium carbonate
  LumenHance manganese chloride
  Macrotec technetium Tc-99m albumin aggregated
  Maxibar barium sulfate
  MDP technetium Tc-99m medronate
  Mepral omeprazole
  MultiHance gadobenate dimeglumine
  Myonal eperisone
  Phosphotec technetium Tc-99m pyrophosphate
  Polibar barium sulfate
  ProHance gadoteridol
  Protonix pantoprazole
  Readi-CAT barium sulfate
  Rubratope-57 cyanocobalamin Co-57
  Sensatrast barium sulfate
  SonoRx simethicone coated cellulose suspension
  SonoVue sulfur hexafluoride
  Tagitol V barium sulfate
  Techneplex technetium Tc-99m pentetate
  Ultravist iopromide
  Varibar barium sulfate
  VoLumen barium sulfate

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.